HCPCS code J7508 – Extended-release oral tacrolimus (Astagraf XL)

Key takeaways

HCPCS code J7508 describes tacrolimus, extended release (Astagraf XL), oral, 0.1 mg, so one unit equals 0.1 mg dispensed.

Medicare Part B covers J7508 when the patient had Part A at the time of the transplant, with claims sent to the DME MAC.

J7508 is for Astagraf XL only. Immediate-release tacrolimus bills as J7507, and Envarsus XR bills as J7503.

KX goes on a Medicare line only when the transplant date is on file and the A52474 conditions are met.

Pabau’s claims management software pre-fills claims from the patient record and tracks each one to payment, so unit and NDC errors surface early.

HCPCS code J7508 covers Astagraf XL, billed per 0.1 mg

HCPCS code J7508 is the Level II code for tacrolimus, extended release (Astagraf XL), oral, 0.1 mg. CMS maintains the HCPCS Level II code set, which covers drugs and supplies that CPT codes don’t describe. One billing unit equals 0.1 mg of tacrolimus dispensed.

Tacrolimus, first developed as FK506, is a calcineurin inhibitor. It suppresses the T-cell response that drives rejection after a solid organ transplant. Astagraf XL, made by Astellas, is the once-daily extended-release capsule the code names.

J7508 sits in the J7500 to J7599 range for immunosuppressive drugs. Keep this quick reference beside the dispensing record when you build the claim.

J7508 covers one product, and several close cousins bill elsewhere

J7508 covers Astagraf XL dispensed as maintenance therapy to prevent organ rejection. Its FDA label approves it for prophylaxis of organ rejection in kidney transplant recipients. Claims for other organs face closer medical necessity review.

The label also carries a boxed warning about increased mortality in female liver transplant patients. These products fall outside J7508, and billing one of them under it is a costly mistake:

• Immediate-release tacrolimus: Prograf and its generics bill as J7507, per 1 mg. Never report them under J7508.
• Envarsus XR: This other extended-release tacrolimus has its own code, J7503, billed per 0.25 mg. The two extended-release products are not interchangeable on a claim.
• Intravenous tacrolimus: IV tacrolimus bills as J7525, per 5 mg. J7508 is strictly oral.
• Topical formulations: Topical tacrolimus (Protopic) is not billable under J7508.
• Off-label non-transplant uses: Payer policies tie J7508 coverage to transplant indications, so off-label claims face medical necessity scrutiny.

Check the dispensed product against the current CMS HCPCS descriptors at the time of service, because descriptors can change each year.

J7508, J7507 and J7503 each count units differently

The most common error in tacrolimus billing is matching the code to the drug instead of the product. Three oral tacrolimus codes exist, and each has its own billing unit. Oral cyclosporine, a different calcineurin inhibitor, adds a code billers often mix up with them.

Units are where a wrong code does the most damage. The same 5 mg daily dose is 50 units under J7508, 5 units under J7507 and 20 units under J7503. Over a 30-day fill, that one dispense turns into three very different unit counts.

When a patient moves from IV tacrolimus (J7525) after surgery to oral maintenance, switch codes at that point. Report J7508 only once the patient is on Astagraf XL, not on immediate-release capsules.

Medicare Part B pays for J7508 after a covered transplant

Medicare Part B, not Part D, covers HCPCS code J7508 for qualifying transplant recipients. The patient must have been enrolled in Part A at the time of the transplant, and in Part B when the drug is dispensed. A transplant that predates Part A enrollment falls outside this benefit, and Part D may cover the drug instead.

The Consolidated Appropriations Act, 2021 added a Part B immunosuppressive drug benefit that started in January 2023. It lets some kidney recipients keep drug coverage after their other Medicare coverage ends 36 months post-transplant. Confirm current eligibility with the applicable Medicare Administrative Contractor (MAC).

Part B oral immunosuppressives are billed to the DME MAC by a pharmacy enrolled as a DMEPOS supplier. The DME MACs’ Immunosuppressive Drugs LCD (L33824) and its policy article A52474 set the coverage rules. A refill can now cover up to a 90-day supply.

When a patient has both Medicare and commercial coverage, coordinate carefully. Billing J7508 under Part D when Part B is the correct primary payer triggers a coordination-of-benefits denial. It can also become a billing compliance issue.

How a J7508 claim moves from prescription to payment

A J7508 claim passes through five stages before anyone gets paid. Knowing who touches it at each one tells you where an error usually starts.

1. The transplant team writes the order. A signed standard written order names the drug, dose, frequency and quantity. The chart records the transplant date and the organ.
2. The pharmacy dispenses and records it. The dispensing record captures Astagraf XL, the NDC on the package, the milligrams dispensed and the date.
3. The claim goes out in the right format. A retail pharmacy billing the DME MAC uses the NCPDP standard, where the NDC replaces the HCPCS code. Other 837P and paper claims carry J7508 and its units.
4. The supplying fee rides along. Policy article A52474 covers one unit of Q0511 for the first covered immunosuppressive drug dispensed in a 30-day or 90-day period.
5. The payer answers on the remittance. A paid line closes the loop. A denied line comes back with a Claim Adjustment Reason Code (CARC), often paired with a Remittance Advice Remark Code (RARC).

Commercial plans and Medicaid set their own formats, so check each payer’s billing guide before the first claim goes out.

Bill J7508 correctly in six steps

Billing HCPCS code J7508 correctly comes down to six elements on every claim. Get them right once and each refill claim follows the same pattern.

1. Confirm the transplant diagnosis code. Attach the Z94.x ICD-10-CM code for the transplanted organ: Z94.0 (kidney), Z94.4 (liver), Z94.1 (heart) or Z94.2 (lung). This establishes medical necessity for Part B coverage.
2. Calculate units from dispensed milligrams. J7508 bills per 0.1 mg, so multiply the milligrams dispensed by 10. A 60 mg dispense is 600 units. Never bill per prescription, capsule count or day’s supply.
3. Attach the 11-digit NDC. Report the NDC in 5-4-2 format, in box 24 of the CMS-1500 with its qualifier or in loop 2410 of the 837P. For clean claim submission, the NDC must match the package dispensed.
4. Send the claim to the right contractor. Part B oral immunosuppressives go to the DME MAC, not the Part B MAC. Confirm the place of service matches where the patient received the drug.
5. Verify prior authorization status. Medicare Part B generally does not require PA for transplant immunosuppressants, but commercial payers often do. Check insurance eligibility and benefits before dispensing to commercial patients.
6. Add KX or GY on Medicare claims. Policy article A52474 allows KX only when four conditions hold. The supplier has the transplant date from the practitioner and keeps that record on file. The patient had Part A at the transplant, and the transplant date precedes the date of service. When coverage criteria aren’t met, the line takes GY instead.

A worked example: One month of Astagraf XL

Take a kidney recipient on Astagraf XL 5 mg once daily, with a transplant that Medicare Part A covered. A 30-day fill of 5 mg capsules is 150 mg, so the line reads J7508 × 1,500 units.

The diagnosis is Z94.0, and the NDC comes off the 5 mg package in hand. With the transplant date on file, the line takes KX. One unit of Q0511 covers the supplying fee for the period.

Documentation that holds up when a payer audits J7508

Payers auditing J7508 claims look for a consistent set of records. A missing piece here is the second most common denial pathway after a missing NDC.

• Transplant date and organ type: The medical record must confirm the transplant and the organ transplanted. This supports the diagnosis code and the need for ongoing immunosuppression.
• Standard written order: It names the patient, the order date, the drug, the quantity, and the treating practitioner with a signature. A new order is needed whenever the dose or frequency changes.
• Pharmacy dispensing record: It must show the product name (Astagraf XL), the NDC, the quantity in milligrams and the dispense date. This record reconciles units billed to units dispensed.
• NDC on the claim: Medicaid requires it in every state, and so do most commercial payers. Many Medicare contractors and trading partners expect it too.
• DME MAC policy requirements: L33824 and its policy article may call for added documentation, such as proof of transplant status or refill contact records.

Keep a transplant billing file for each patient, with the transplant summary, current orders and dispense records. It speeds up audit responses. A superbill that captures the NDC, units and diagnosis codes at the point of service makes that file easy to build.

Prior authorization depends on who pays

Prior authorization for immunosuppressants follows a split pattern between Medicare and commercial payers. Mixing up the two rules is how a clean dispense turns into a denial.

Medicare Part B: It generally does not require prior authorization for tacrolimus for a qualifying transplant recipient. The diagnosis codes, the KX criteria and the chart documentation do that job instead.

Commercial payers: Most commercial plans require PA for immunosuppressants before the first dispense. Typical criteria include a documented transplant, the transplant specialist’s attestation and the center’s dosing protocol. Dispensing before PA is on file leads to a retroactive denial that is hard to overturn.

Medicaid: State programs vary. Many require PA for an initial period, commonly 12 months, with annual renewal. Some states exempt transplant immunosuppressants under fee-for-service, while managed Medicaid plans usually require PA.

Before you submit: A J7508 checklist

Run through these six checks on every J7508 claim, refills included. Each one maps to a denial reason further down.

• The product dispensed is Astagraf XL, not Prograf, a generic or Envarsus XR.
• Units equal milligrams dispensed × 10, not capsules or days.
• The NDC matches the strength and pack size on the shelf today.
• A covered transplant diagnosis code sits on the claim.
• KX is on the line only when the transplant date is on file and Part A applied at the transplant.
• A commercial claim has its PA number attached, and the PA hasn’t lapsed.

Common J7508 denials and the fix for each

J7508 denials cluster around six root causes. The table maps each one to the Claim Adjustment Reason Code (CARC) payers most often return and the action that resolves it. For the wider code sets, see our guide to denial codes.

Good denial management for J7508 tracks each denial by root cause, not only by CARC. A month of tagged denials often points to one workflow step, such as an NDC skipped at the point of dispense.

Mistakes that keep J7508 claims coming back

Most repeat denials trace to habits rather than one-off slips. These are the ones worth retraining:

• Counting capsules as units. Thirty 5 mg capsules are 1,500 units of J7508, never 30.
• Copying last month’s NDC. A dose change often means a new strength, and each strength has its own NDC.
• Coding by molecule. “Tacrolimus” on the script doesn’t settle the code. The product on the label does.
• Adding KX by default. KX is an attestation that the four A52474 conditions hold, so it needs the transplant date on file.
• Sending every transplant patient to the DME MAC. A transplant that came before Part A enrollment belongs with Part D instead.

Payment for J7508 follows ASP, and the NDC has to match

Medicare Part B reimburses J7508 under the Average Sales Price (ASP) methodology, per 0.1 mg unit. The payment rate is ASP plus 6%, or ASP plus 4.3% under mandatory sequestration. CMS updates ASP rates quarterly, so pull the current rate from the CMS Physician Fee Schedule and ASP Drug Pricing files.

Commercial reimbursement for J7508 is contract-specific. Many commercial plans pay at AWP minus a discount, which can differ a lot from the Medicare ASP rate. Model your Astagraf XL reimbursement by payer and flag contracts that approach or fall below acquisition cost.

NDC reporting requirements

Medicaid requires the 11-digit NDC on every J7508 claim. Report it in 5-4-2 format, taken from the package dispensed, not from a drug database. The NDC quantity must use the unit of measure as dispensed, typically “each” for capsules.

As an example, Astagraf XL 0.5 mg capsules carry NDC 00469-0647-73. A 30-capsule dispense of that strength is 15 mg, so it bills as 150 units of J7508. Each strength and pack size has its own NDC, so copy it from the package in hand.

CMS publishes a quarterly crosswalk file that maps NDCs to HCPCS codes. The AAPC HCPCS code lookup and the PGM Billing HCPCS tool can help confirm your NDC maps to J7508. When a Prograf or Envarsus XR NDC lands on a J7508 line, it shows up as a formulation mismatch denial.

The safest place to capture the NDC is the dispense itself. By the time a biller reviews the claim, the package has usually left the pharmacy.

How Pabau keeps J7508 claims on track

In many transplant practices, J7508 claims are still checked by hand. A biller confirms the product, recounts units and copies the NDC from the dispensing record. Because tacrolimus is lifelong, one slip can repeat on every refill.

Pabau, the practice management platform we build, keeps patient records, prescribing notes and claims in one system. Its claims management software pre-fills the claim from the patient record and checks required fields before it can be sent. In the US, claims go out through Claim.MD, with eligibility checks and remittance posting built in.

Each claim’s status and denial reason sit on the same record as the patient’s orders. A recurring unit or NDC error shows up after one refill instead of six, so staff spend less time on resubmissions.

Keep every J7508 refill claim clean

Pabau pre-fills claims from the patient record, checks required fields before submission and tracks each claim to payment. Denial reasons for every refill sit in one place.

Book a demo

Conclusion

J7508 rewards a practice that treats it as a product code rather than a drug code. Confirm Astagraf XL on the label, count in 0.1 mg units and send the claim to the DME MAC. Those three habits remove most of the denials on this page.

The trade-off is upfront work. Building the transplant file and KX evidence takes time on the first claim, but tacrolimus is lifelong. Every refill after that reuses the same file.

Book a demo to see how Pabau tracks your J7508 claims from dispense to payment.

Continue your research

Need a denial management framework for specialty drug claims? Denial management in healthcare covers the end-to-end process for tracking, appealing and preventing claim denials across J-code billing.

Billing the immediate-release version instead? HCPCS code J7507 explains Prograf and generic tacrolimus billing at 1 mg per unit.

Managing a patient on sirolimus too? HCPCS code J7520 covers oral sirolimus, another immunosuppressant billed to the DME MAC.

Want to understand the broader billing compliance picture? Medical billing compliance outlines documentation standards, NDC reporting rules and audit readiness for specialty practices.

Looking to improve your overall revenue cycle? What is revenue cycle management explains how to structure billing workflows from eligibility through final payment posting.

Frequently asked questions